News About: Pharm. Industry
340 drugs of 11 pharmas cut by 8.38% for providing illegal rebates
340 drugs of 11 pharmaceutical companies which were exposed for provision of illegal rebates were cut price by 8.38% on average.
The Ministry of Health and Welfare(Minister Neung-Hoo Park, MOHW) held the Health Insur...
Pharma industry focusing on products tailored for women
The pharmaceutical industry is focusing on attracting female consumers by specializing their products for women.
Pharmaceutical companies are currently developing whole new products just for the treatment of female-s...
Daewoong’s next management with Co-CEO Jae-Choon Yoon and Seung-Ho Jeon
The management of Daewoong Group announced to carry out the personnel reshuffle and focus on the global vision of 2020.
Daewoong Pharmaceutical(Jong-Wook Lee) held the 58th general meeting of stockholders and appoint...
About 20 pharmas including Hanmi Pharm compete in antithrombotic market
As ‘Brilinta Tab(generic name: ticagrelor),’a AstraZeneca’s antithrombotic, is expired in its PMS(Post-Marketing Surveillance), about 20 Korean pharmaceutical companies including Hanmi Pharm jumped into its market aft...
1 of 3 listed pharmas making net profit/sales ratio even less than 1%
The polarization in profitability is reportedly getting serious as one of 3 listed pharmaceutical companies have a net profit ratio to sales less than 1%.
Yakup Shinmoon(www.yakup.com) analyzed 2017 audit reports tha...
Korea Exchange’s decision on Kyungnam Pharm to make subject to Substantive Examination for Listing Eligibility
The Exchange Korea reviewed possibilities to delist Kyungnam Pharm based on general qualifications in accordance with Article 38 of 2 Item of Number 2 of the KOSDAQ Rules, and officially announced that the company is ...
Daewoong Pharmaceutical signs co-promotion agreement of ‘Foxiga & Xigduo’ with AstraZeneca
Daewoong Pharmaceutical(CEO Jong-Wook Lee) signed a co-promotional partnership agreement of ‘Forxiga(dapagliflozin)’ and ‘Xigduo(dapagliflozin+metformin),’ SGLT-2 inhibitors for the treatment of type 2 diabetes with A...
10 listed pharmas like Samsung Pharm don’t even have an ability to pay interests with operating profits they make
10 listed pharmaceutical companies, such as Samsung Pharm, Binex and Aprogen Pharmaceuticals(formerly known as Schnell Biopharmaceuticals), reportedly have no ability to pay interests for their debts with sales they m...
JW Pharmaceutical’s ‘Emicizumab’ designated as orphan drug treating hemophilia A
‘Emicizumab,’ a hemophilia A treatment which has been widely known to become a global new drug, has also raised attention of patients as being designated as an orphan drug even in Korea.
JW Pharmaceutical announced o...
Samsung Bioepis records KRW 314.8 billion sales and continue losses in operating & net profits
Samsung Bioepis(unlisted, subsidiary of Samsung Biologics) achieved KRW 314.8 billion sales last year based on the audit report on March and grew 113.4% up compared to the year before.
The company continued to make n...
